Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

A screenshot of Luo Xiang, criminal law professor at China University of Political Science and Law, teaching online.[Photo provided to China Daily] Exciting is not a term normally used when studying ...